Q1 2026 Illumina Inc Earnings Call Transcript
Key Points
- Illumina Inc (ILMN) reported Q1 revenue, margin, and EPS above guidance, reflecting strong execution and growth in clinical markets.
- The company raised its 2026 guidance due to Q1 outperformance, indicating confidence in sustained growth.
- NovaSeq X placements exceeded expectations, with over 80 units placed in Q1, driving future consumables growth.
- Clinical sequencing consumable demand grew 20% ex China for the second consecutive quarter, highlighting strong adoption.
- Illumina Inc (ILMN) announced an additional $1.5 billion in share repurchases, demonstrating confidence in its financial position.
- Research and academic markets remain cautious due to funding uncertainty, impacting growth in these segments.
- Sequencing consumables in research and applied markets declined 12% ex China, reflecting ongoing challenges.
- The company faces inflationary pressures related to freight costs and electronic components, impacting margins.
- Microarrays business was down 20% on a Rest of World organic basis, largely due to specific large customers in the direct-to-consumer segment.
- Despite strong Q1 performance, Illumina Inc (ILMN) remains cautious in raising full-year organic growth guidance, indicating potential uncertainties ahead.
Good day, ladies and gentlemen. Welcome to the first-quarter 2026 Illumina earnings conference call. (Operator Instructions)
Please be advised that today's conference is being recorded. I would now like to hand the call over to Head of Investor Relations, Conor McNamara.
Hello, everyone, and welcome to Illumina's first-quarter 2026 earnings call. Today, we will review our financial results released after market close and provide prepared remarks before opening the line for Q&A. Our earnings release is available in the Investor Relations section of illumina.com. Joining me today are Jacob Thaysen, Chief Executive Officer; and Ankur Dhingra, Chief Financial Officer.
Jacob will begin with an update on Illumina's business, followed by Ankur's review of our financials. We will be discussing certain non-GAAP financial measures, and a reconciliation to GAAP can be found in today's release and in the supplementary data on our website. Unless stated otherwise, all growth rates are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
